In the United States, rezafungin isindicated in adults who have limited or no alternative options for the treatment ofcandidemia and invasive candidiasis.[1]
In the European Union, rezafungin is indicated for the treatment of invasive candidiasis in adults.[2]
Rezafungin, while remaining a hydrophilic compound, exhibits a volume of distribution more than twice that of caspofungin.[7] This pharmacokinetic property has supported its investigation for the treatment of deep-seatedCandida infections, including osteomyelitis.[8][9]
In October 2023, theCommittee for Medicinal Products for Human Use of theEuropean Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Rezzayo, intended for the treatment of invasive candidiasis in adults.[2] The applicant for this medicinal product is Mundipharma GmbH.[2] Rezafungin was approved for medical use in the European Union in December 2023.[3]
^abcdefg"Rezzayo EPAR".European Medicines Agency (EMA). 12 October 2023. Retrieved27 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 79".WHO Drug Information.32 (1).hdl:10665/330941.
